{{Rsnum
|rsid=3127599
|Gene=LPAL2
|Chromosome=6
|position=160486102
|Orientation=minus
|GMAF=0.2388
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=LPAL2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 15.0 | 35.4 | 49.6
| HCB | 1.5 | 24.8 | 73.7
| JPT | 1.8 | 16.1 | 82.1
| YRI | 7.0 | 49.3 | 43.7
| ASW | 9.3 | 44.4 | 46.3
| CHB | 1.5 | 24.8 | 73.7
| CHD | 0.0 | 23.9 | 76.1
| GIH | 2.0 | 36.6 | 61.4
| LWK | 7.4 | 48.1 | 44.4
| MEX | 5.2 | 29.3 | 65.5
| MKK | 10.4 | 46.8 | 42.9
| TSI | 6.9 | 44.1 | 49.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3127599
|Name_s=
|Gene_s=LPAL2
|Feature=
|Evidence=PubMed ID:19198611; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. (Initial Sample Size: 1,926 cases, 2,938 controls; Replication Sample Size: 7,073 cases, 7,325 controls); (Region: 6q25.3; Reported Gene(s): SLC22A3,LPAL2,LPA; Risk Allele: 4-SNP haplotype-1); (p-value= 0.000000001).This variant is associated with Coronary artery disease.
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164739977
}}

{{PharmGKB
|RSID=rs3127599
|Name_s=
|Gene_s=LPAL2
|Feature=
|Evidence=PubMed ID:19198611; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. (Initial Sample Size: 1,926 cases, 2,938 controls; Replication Sample Size: 7,073 cases, 7,325 controls); (Region: 6q25.3; Reported Gene(s): SLC22A3,LPAL2,LPA; Risk Allele: 4-SNP haplotype-2); (p-value= 0.000000000000004).This variant is associated with Coronary artery disease.
|Drugs=
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164739979
}}

{{PMID Auto
|PMID=19956433
|Title=Genetics of coronary artery disease: focus on genome-wide association studies.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3127599
|overall_frequency_n=25
|overall_frequency_d=128
|overall_frequency=0.195312
|n_genomes=22
|n_genomes_annotated=0
|n_haplomes=25
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}